Emerald Mutual Fund Advisers Trust Has $2.31 Million Position in Quanterix Co. (NASDAQ:QTRX)

Emerald Mutual Fund Advisers Trust lessened its holdings in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 61.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 216,860 shares of the company's stock after selling 346,387 shares during the period. Emerald Mutual Fund Advisers Trust owned approximately 0.56% of Quanterix worth $2,305,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in QTRX. William Blair Investment Management LLC bought a new stake in Quanterix in the 4th quarter valued at $11,290,000. Pier Capital LLC increased its stake in Quanterix by 32.8% during the fourth quarter. Pier Capital LLC now owns 679,680 shares of the company's stock valued at $7,225,000 after acquiring an additional 167,882 shares during the period. Valmark Advisers Inc. lifted its position in shares of Quanterix by 88.3% in the 4th quarter. Valmark Advisers Inc. now owns 210,878 shares of the company's stock worth $2,242,000 after acquiring an additional 98,883 shares during the period. Easterly Investment Partners LLC grew its holdings in shares of Quanterix by 9.0% during the 4th quarter. Easterly Investment Partners LLC now owns 954,995 shares of the company's stock worth $10,152,000 after purchasing an additional 78,862 shares in the last quarter. Finally, Portolan Capital Management LLC increased its position in shares of Quanterix by 2.7% during the fourth quarter. Portolan Capital Management LLC now owns 2,587,824 shares of the company's stock valued at $27,509,000 after purchasing an additional 67,138 shares during the period. Institutional investors and hedge funds own 86.48% of the company's stock.

Quanterix Price Performance

Shares of QTRX stock traded up $0.24 during trading hours on Friday, hitting $6.01. 477,565 shares of the company's stock were exchanged, compared to its average volume of 552,314. The stock's 50-day moving average is $6.35 and its 200-day moving average is $9.35. The stock has a market cap of $233.12 million, a price-to-earnings ratio of -5.67 and a beta of 1.35. Quanterix Co. has a 52 week low of $4.67 and a 52 week high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $35.16 million for the quarter, compared to analyst estimates of $34.93 million. Equities research analysts forecast that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on QTRX shares. Scotiabank restated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Leerink Partners reaffirmed a "market perform" rating and set a $8.00 price objective (down from $12.00) on shares of Quanterix in a report on Wednesday. Canaccord Genuity Group cut their target price on Quanterix from $20.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Finally, Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $16.20.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.